期刊文献+

HIA方案治疗复发难治性急性髓系白血病2例并文献复习

下载PDF
导出
摘要 目的探讨以HIA方案化疗对复发难治性急性髓系白血病的疗效。方法采用以HIA方案治疗复发难治性急性髓系白血病2例,化疗2个疗程。结果 2例均完全缓解。结论 HIA方案对复发难治性急性髓系白血病患者是有效的。
出处 《浙江实用医学》 2013年第3期227-228,共2页 Zhejiang Practical Medicine
  • 相关文献

参考文献12

  • 1Estey E H. Treatment of relapsed and refractory acute myeloidleukemia. Leukemia,2000,14 : 476.
  • 2Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocytecolony - stimulating factor with low - dose cytosine arabinoside andaclarubicin for previously treated acute myelogenous leukemia : a pilotstudy. Leukemia, 1995,9(1) : 10.
  • 3Hashmi K U,Khan B,Ahmed P,et al.FLAG — IDA in the treatment ofrefractory/relapsed acute leukemias: single centre study. J Pak MedAssoc,2005,55(6) :234.
  • 4Montesinos P,Rubia Jdl,Orti G,et al.FLAG- IDA regimen (fludara-bine,cytarabine,idarubicin and G - CSF) in the treatment of patientswith high2 risk acute myeloid leukemia and myelodysp lastic syn-dromes .Blood (ASH Annual Meeting Abstract),2007,110:2866.
  • 5Yavuz S,Paydas S, Disel U,et al. IDA - FLAG regimen for the therapyof primary refractory and relapse acute leukemia : a single - centerexperience . Am J Ther,2006,13 : 389.
  • 6急性髓系白血病(复发难治性)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(12):887-888. 被引量:92
  • 7Staber P B,Linkesch W,Zauber D,et al. Common alterations in geneexpression and increased proliferation in recurrent acute myeloidleukemia. Oncogene,2004,23(4) :894.
  • 8Hur M,Chang Y H,Lee D S, et al. Immunophenotypic and cytogeneticchanges in ante leukemia at relapse. Clin Tah Haematol, 2001, 23(3):173.
  • 9唐加明,孟凡义,陈安薇.难治性急性髓系白血病(M_(2a))的基因表达谱[J].癌症,2005,24(6):676-679. 被引量:1
  • 10Michieli M, Dminni D, Ermacora A, et al. P - glycoprotein,lung resis-tance -related protein and multidrug resistance associated protein inde novo acute non - lymphocytic leukemias : biological and clinicalimplications. Br J Haematol,1999,104(2) : 328.

二级参考文献16

  • 1Hur M, Chang YH, Lee DS, et al. Immunophenotypic and cytogenetic changes in acute leukemia at relapse [J]. Clin Lab Haematol, 2001,23(3): 173-179.
  • 2Michieli M, Dmiani D, Ermacora A, et al. P-glycoprotein,lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias:biological and clinical implications [J]. Br J Haematol, 1999,104(2): 328-335.
  • 3van den Heuvel-Eibrink MM, Wiemer EAC, Prins A, et al.Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) [J]. Leukemia, 2002,16(5) :833-839.
  • 4Preisler HD, Gopal V. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment [J]. Leuk Res,1994,18(3): 149-160.
  • 5Estey E. Treatment of refractory AML [J]. Leukemia, 1996,10(6) :932-936.
  • 6Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [J].Blood, 2002, 100(7) :2393-2398.
  • 7Schaeffer HJ, Catling AD, Eblen ST, et al. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade [J]. Science, 1998,281 (5383): 1668-1671.
  • 8Staber PB, Linkesch W, Zauner D, et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia [J]. Oncogene, 2004,23 (4):894-904.
  • 9Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells [J]. Blood,2003,102(3) :987-995.
  • 10Raza A, Preisler HD, Day R, et al. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. A leukemia intergroup study [J]. Blood, 1990,76(11):2191-2197.

共引文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部